Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years.

ABSTRACT:

Background and objectives

Limited postauthorization safety data for the Pfizer-BioNTech coronavirus disease 2019 vaccination among children ages 5 to 11 years are available, particularly for the adverse event myocarditis, which has been detected in adolescents and young adults. We describe adverse events observed during the first 4 months of the United States coronavirus disease 2019 vaccination program in this age group.

Methods

We analyzed data from 3 United States safety monitoring systems: v-safe, a voluntary smartphone-based system that monitors reactions and health effects; the Vaccine Adverse Events Reporting System (VAERS), the national spontaneous reporting system comanaged by the Centers for Disease Control and Prevention and Food and Drug Administration; and the V

SUBMITTER: Hause AM 

PROVIDER: S-EPMC9706403 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature